Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | ERCC5 | P28715 | 5/20 | 0.56 |
| ▸ | FEN1 | P39748 | 5/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.55 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.51 |
| ▸ | GCK | P35557 | 1/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.49 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6947647 | 0.93 | PTPN1 (0.70) | PTPN1MEN1KMT2AERCC5FEN1 | |
| SCHEMBL6948385 | 0.90 | PTPN1 (0.70) | PTPN1MEN1KMT2AERCC5FEN1 | |
| SCHEMBL6951340 | 0.88 | PTPN1 (1.00) | PTPN1MEN1KMT2AERCC5FEN1 | |
| SCHEMBL13427458 | 0.88 | MEN1 (0.71) | PTPN1MEN1KMT2ANR4A2SMPD1 | |
| SCHEMBL11683646 | 0.86 | PTPN1 (0.72) | PTPN1ERCC5FEN1NR4A2MAOB | |
| SCHEMBL6945638 | 0.84 | PTPN1 (0.64) | PTPN1MEN1KMT2AERCC5FEN1 | |
| SCHEMBL13758580 | 0.82 | MEN1 (0.63) | PTPN1MEN1KMT2ANR4A2SMPD1 | |
| SCHEMBL6946229 | 0.82 | PTPN1 (0.84) | PTPN1ERCC5FEN1NR4A2SMPD1 | |
| SCHEMBL6951595 | 0.82 | EGFR (0.57) | PTPN1EGFR | |
| SCHEMBL2451027 | 0.81 | MEN1 (0.71) | PTPN1MEN1KMT2ANR4A2SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280849-A1 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-11-13 | — | — | US | claimed |
| WO-2006129134-A1 | SYNERGIC COMBINATIONS COMPRISING A STYRYLQUINOLINE COMPOUND AND OTHER HIV INFECTION THERAPEUTIC AGENTS | BIOALLIANCE PHARMA (FR) | 2006-12-07 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2025-01-02 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-12060334-B2 | 3-substituted phenazine derivatives as antimicrobial agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-08-13 | — | — | US | disclosed |
| US-12030888-B2 | Himastatin derivatives, and processes of preparation thereof, and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-09 | — | — | US | disclosed |
| CN-111565716-B | Method of using dipivefrin | 因斯格尼斯疗法有限公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-3416958-B1 | THIOSEMICARBAZIDES AS ANTIFUNGAL COMPOUNDS AND THEIR USES | DANA FARBER CANCER INST INC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20220289689-A1 | 3-SUBSTITUTED PHENAZINE DERIVATIVES AS ANTIMICROBIAL AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2022-09-15 | — | — | US | disclosed |
| US-20220289750-A1 | HIMASTATIN DERIVATIVES, AND PROCESSES OF PREPARATION THEREOF, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-09-15 | — | — | US | disclosed |
| US-20070259823-A1 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259823-A1 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC (US) | 2007-11-08 | — | — | US | disclosed |
| US-7250421-B2 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250421-B2 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| WO-2006129134-A1 | SYNERGIC COMBINATIONS COMPRISING A STYRYLQUINOLINE COMPOUND AND OTHER HIV INFECTION THERAPEUTIC AGENTS | BIOALLIANCE PHARMA (FR) | 2006-12-07 | — | — | WO | disclosed |
| EP-1082121-A4 | HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2003-02-05 | — | — | EP | disclosed |
| US-6380249-B1 | HIV integrase inhibitors | MERCK & CO., INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1082121-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999062520-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030888-B2 | Himastatin derivatives, and processes of preparation thereof, and uses thereof | PCSK9, HMGCR, PCSK7 | PTPN1 4505/4885MEN1 97/4885KMT2A 2415/4885 |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | PTPN1 2765/4885MEN1 419/4885KMT2A 3596/4885 |
| US-20080280849-A1 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents | CTSL, CDKL1, QTRT2 | PTPN1 4667/4885MEN1 3557/4885KMT2A 1290/4885 |
| US-20220289689-A1 | 3-SUBSTITUTED PHENAZINE DERIVATIVES AS ANTIMICROBIAL AGENTS | ROS1, NOX4, NOX5 | PTPN1 346/4885MEN1 4306/4885KMT2A 3548/4885 |
| US-20070259823-A1 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | DCK, DTYMK, DUT | PTPN1 4577/4885MEN1 4619/4885KMT2A 1467/4885 |
| US-20220289750-A1 | HIMASTATIN DERIVATIVES, AND PROCESSES OF PREPARATION THEREOF, AND USES THEREOF | PCSK9, HMGCR, PCSK7 | PTPN1 4505/4885MEN1 97/4885KMT2A 2415/4885 |
| US-12060334-B2 | 3-substituted phenazine derivatives as antimicrobial agents | ROS1, NOX4, NOX5 | PTPN1 346/4885MEN1 4306/4885KMT2A 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.